Navigation Links
Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology
Date:3/9/2010

CAMBRIDGE, Mass., March 9 /PRNewswire/ -- Researchers at MIT are eagerly anticipating the summer delivery of Elekta Neuromag®, a system that uses magnetoencephalography or MEG to explore brain function. MEG can detect the very weak magnetic fields arising from electrical activity in the brain, and allows researchers to monitor the timing of brain activity with millisecond precision. MIT researchers will use MEG to study normal cognition in children and adults, as well as the neural basis of autism, depression, schizophrenia and other brain disorders.

“MIT is exceptionally well positioned to benefit from a MEG facility on our campus,” says Charles Jennings, Ph.D., director of neurotechnology at the McGovern Institute for Brain Research. “MIT is among the country’s leading centers for neuroscience research, with a community of investigators that studies the brain at every level, from molecules and cells to human cognition and computational modeling. We also have strong programs to study a wide range of brain disorders, which will benefit greatly from access to MEG technology.”

"MIT's worldwide reputation for advancing knowledge in science and technology for nearly 150 years makes its acquisition of Elekta Neuromag particularly gratifying, and we're proud to be a part of it," says Stephen Otto, Chairman of Elekta's Neuromag Business. "And it is fitting that this institution, especially, will become Elekta's latest MEG site, as MEG was invented by David Cohen at MIT."

The Elekta Neuromag system will be housed in the Martinos Imaging Center within the Brain and Cognitive Sciences complex, home to the McGovern Institute of Brain Research, the Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences. Delivery of the system is expected in June and it should be operational by the fall of 2010.

The following are examples of planned MEG research projects at MIT:

  • Prof. John Gabrieli, director of the Martinos Imaging Center, will use MEG to study the neural and genetic basis of autism, dyslexia and other developmental disorders. By combining MEG with other brain imaging modalities, such as magnetic resonance imaging (MRI) and electroencephalography (EEG), Dr. Gabrieli plans to search for differences in brain activation in subjects with different genetic variants that have been linked to these conditions. "Our goal is to correlate the changes in brain function with genetic risk factors, and in turn identify categories of patients for whom optimal treatment strategies could be tailored," he says.

  • Prof. Robert Desimone, director of the McGovern Institute, plans to study the neural basis of attention. Animal studies have indicated that high frequency brain waves known as gamma oscillations become synchronized across brain areas as these areas communicate with each other to control attention. He plans to extend this work to humans using MEG, and he hopes that this will provide new insights into the basis of diseases such as schizophrenia. "Gamma oscillations are disrupted in schizophrenia, and we think this may help explain why people with schizophrenia often experience difficulty organizing their thoughts and perceptions into a coherent and meaningful whole," Dr. Desimone explains.

  • Prof. Christopher Moore, an investigator at the McGovern Institute, seeks to understand how the cerebral cortex processes rapid sensory information. Based on his work on cortical circuitry, Dr. Moore has developed a biophysical model to account for the MEG signal. "Our aim is to link the signals that we can record from human subjects to the underlying brain mechanisms that give rise to those signals," he says. "Arguably, we will never fully understand normal cognition or the ways that cognition fails in brain disorders unless we can achieve this deep circuit understanding."

Other MIT faculty members expect to use the new MEG facility for a variety of studies, including MEG source localization; the neural basis of age-related changes in cognition; how individuals differ in their processing of social cues such as faces; cognitive deficits in autism spectrum disorder; the processing of complex visual scenes; neural mechanisms of speech and comprehension; how children and adults infer and reason about the mental states of other people; neural mechanisms of motor control and many other studies.

"In many ways the brain is a 'black box.' It is so complex -- comprising 100 billion neurons and a trillion or more synapses -- it's not surprising it's challenging to study," Dr. Jennings notes. "But with MEG I think we'll succeed in shining a little light in there."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

About the McGovern Institute for Brain Research

The McGovern Institute for Brain Research at MIT is led by a team of world-renowned, neuroscientists committed to meeting two great challenges of modern science: understanding how the brain works and discovering new ways to prevent or treat brain disorders. The McGovern Institute was established in 2000 by Patrick J. McGovern and Lore Harp McGovern, who are committed to improving human welfare, communication and understanding through their support for neuroscience research. The director is Robert Desimone, formerly the head of intramural research at the National Institute of Mental Health. Further information is available at: mcgovern.mit.edu

SOURCE Elekta

Back to top

RELATED LINKS
http://www.elekta.com

'/>"/>

SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Massachusetts Today
2. CVS/pharmacy to Provide H1N1 Vaccinations in Massachusetts, Virginia and Orange County, California
3. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
4. Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution
5. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
6. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
7. PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
8. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
9. The Hamner Institutes and Oslo Cancer Cluster Announce Partnership
10. Pharmaceutical Institute Launches New Training Resources Focused on Employers and Retail Pharmacy
11. US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s leading ... Big Game. Take the stress out of your party preparation – follow these easy, ... every stage of the game. , “The key to hosting a successful game-day party ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
Breaking Medicine News(10 mins):